{"id":996619,"date":"2026-08-19T08:15:17","date_gmt":"2026-08-19T12:15:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/"},"modified":"2026-08-19T08:15:17","modified_gmt":"2026-08-19T12:15:17","slug":"maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/","title":{"rendered":"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies"},"content":{"rendered":"<div class=\"mw_release\">\n<p>ROCKVILLE, Md., Aug.  19, 2026  (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 off-target nomination assays. Available through MaxCyte\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qrxN4EkvmKBdqPUPOh2Lj9P316FMY9v9zFxZHP0O0OrA449RQCe8XomGJA_gqZAH-mOylEh3fjSTE36PvbenIA==\" rel=\"nofollow\" target=\"_blank\">SeQure\u2122<\/a> service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs).<\/p>\n<p>SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify overlapping and distinct nominated sites and to prioritize regions for confirmation assays. CHANGE-seq-BE is a sensitive, unbiased biochemical off-target nomination method for base editors, and ONE-seq-BE is the only nomination assay for base editors that provides full visibility of population-specific genetic variants that may impact off-target activity. By combining these two assays, MaxCyte is uniquely positioned as a single-source provider of orthogonal nomination assays for base editors. Together with SeQure\u2019s existing confirmation assays for quantitative off-target editing measurement and structural variation detection, therapeutic developers can confidently assess off-target risks in the relevant cell and tissue context. This is especially important as developers work to align with evolving regulatory expectations \u2013 including recent <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s00CW6Uv7OhYw0zj45gPjuzkyhS5TLHubX-JqOOGiOtxVg3I-z-UgaBh_QhCadTKEv9_pt6rWgeXw02TvUK_pqphlRmLnwBd58U765ngkzYe1BpiR3ISjbNecEv7kVRKMkwz1w5uwu7TJU17ClK3kV5Eh615YwgnvdGJkaAYVvuBmZRhfEhIyiHVNFTNB9OPuev35L6vcUSk2EhIzknXgYtqTIK7szrbnuh22oKJPTUjlsPtoVdgsrvAU4szcfSd\" rel=\"nofollow\" target=\"_blank\">FDA guidance<\/a> on off-target editing and genome safety \u2013 with a growing emphasis on orthogonal assays, assay sensitivity, and modality-appropriate methods.<\/p>\n<p>Maher Masoud, President and CEO at MaxCyte, commented: \u201cBase editors are creating new opportunities for therapeutic development, while also requiring safety assessment strategies that reflect their mechanisms of action. The addition of CHANGE-seq-BE and ONE-seq-BE to our SeQure services gives developers access to sensitive, orthogonal off-target assessment capabilities that can help them to better understand and mitigate off-target risk, building stronger data packages for clinical development.\u201d<\/p>\n<p align=\"left\">For more information about MaxCyte\u2019s SeQure services, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aSEs5hUzCdmq8r4Q002yl4A2NEvIuJWOB0acGvixEpIH5o6xAHm0qFRNI5LMRUQKit8gFI1n_Qclj2KD7shzL4qW6vsxlTFLwRJqCj_8NU0=\" rel=\"nofollow\" target=\"_blank\">maxcyte.com\/sequre<\/a>.<\/p>\n<p>\n        <strong>About MaxCyte<\/strong>\n      <\/p>\n<p>At MaxCyte\u00ae, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation\u00ae\u00a0technology and SeQure\u2122 gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we&#8217;ve been advancing cell engineering, shaping the future of medicine.\u00a0<\/p>\n<p>Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aSEs5hUzCdmq8r4Q002yl6JPRCGb5IdhmKT-FT6MU3PeTKgZJFyMFj3eS6aLZ--EjCYNz9J_GnP5iY9oP6hM_g==\" rel=\"nofollow\" target=\"_blank\">maxcyte.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JtP8Swv6ElD71M56MloRR79iQWDr8zERDgqNlJ9AfgLDfmdT6UqlnkYckNKmjzPOfuTOHOQQaZC3NRAGeXVhSfoIvqhTpvkL8lu1o_Nvinc=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uq0b7awxHD2yXExNhOedEv2fEdzkwR_PCNapUo1h9h3TlO5QLbGbpJMI0jtEszdudAyVHfEKjNuYZgYo7nj5O64WwEdlu5cVHD_jAHPHmNg=\" rel=\"nofollow\" target=\"_blank\">Bluesky<\/a>.<\/p>\n<p>\n        <strong>MaxCyte Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Gilmartin Group<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Erik Abdow<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8QfN1K0BPkioJrltI5mwlnU7rs62WP5vWGkGCCwg5x4wXSmU2ggB14dAUOrt5P-MSWs0MzWkhU1TS4SmhOy7Hg==\" rel=\"nofollow\" target=\"_blank\">ir@maxcyte.com<\/a><\/u><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Oak Street Communications<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Kristen White<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dBNe5YyQvi2T2hFs1a0ZMIiPi6iw3v3ljLw_4lN7MGcygdZj1QVyGY-Vrc4u-DORdjltLa-zEe3E720J_wQinW9nR6w80q1yCa8j5Kum1EnRPwmw5j4rpYwqgoKayUhy0u54i0FHX8G2tDDxX871Fw==\" rel=\"nofollow\" target=\"_blank\">kristen@oakstreetcommunications.com<\/a><br \/>415.608.6060<\/p>\n<p>\n        <strong>Editorial contact for further information or follow-up:<\/strong><br \/>\n        <br \/>\n        <strong>Sarah Ballard<\/strong> at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BCzjfBrcmaTGjawcO2izxS42WhZ3HeNhPWs6SwDM8vPwTy4kGIfxPx6jXb99rOhOzHBP113BR6YsbxRfDe27ITt19YOZ8zC9itqpoGUGzWdZflubxd93IKlWopLXVspv\" rel=\"nofollow\" target=\"_blank\"><strong><u>kdm communications limited<\/u><\/strong><\/a>, St Neots, UK<br \/>Tel. +44 (0)1480 405333\u00a0\u00a0 Fax: +44 (0)1480 477833<br \/>email <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vc-RuXdh8E9z0eGpjb4KvqEjWmxz-47hNV_F-I1J-ME99iF9lucKNUG7Gf-L-OA1kohdk_nLMRfU2ikT4c3GCy7Kp65o2dc8kXNcTJDoo58fdkcRtT5vsLzUkPRGtZNq\" rel=\"nofollow\" target=\"_blank\">ideas@kdm-communications.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGIxYTMwNTItZjVkNy00NWRkLThmZTItNThkMWIwNDRhNTIzLTEyMTY3MzEtMjAyNi0wOC0xOS1lbg==\/tiny\/MaxCyte-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 off-target nomination assays. Available through MaxCyte\u2019s SeQure\u2122 service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs). SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify overlapping and distinct nominated sites and to prioritize regions for confirmation assays. CHANGE-seq-BE is a sensitive, unbiased biochemical off-target nomination method for base editors, and ONE-seq-BE is the only nomination assay for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-996619","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 off-target nomination assays. Available through MaxCyte\u2019s SeQure\u2122 service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs). SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify overlapping and distinct nominated sites and to prioritize regions for confirmation assays. CHANGE-seq-BE is a sensitive, unbiased biochemical off-target nomination method for base editors, and ONE-seq-BE is the only nomination assay for &hellip; Continue reading &quot;MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-19T12:15:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies\",\"datePublished\":\"2026-08-19T12:15:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/\"},\"wordCount\":465,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/\",\"name\":\"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg=\",\"datePublished\":\"2026-08-19T12:15:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/","og_locale":"en_US","og_type":"article","og_title":"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies - Market Newsdesk","og_description":"ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 off-target nomination assays. Available through MaxCyte\u2019s SeQure\u2122 service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs). SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify overlapping and distinct nominated sites and to prioritize regions for confirmation assays. CHANGE-seq-BE is a sensitive, unbiased biochemical off-target nomination method for base editors, and ONE-seq-BE is the only nomination assay for &hellip; Continue reading \"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-19T12:15:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies","datePublished":"2026-08-19T12:15:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/"},"wordCount":465,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/","name":"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg=","datePublished":"2026-08-19T12:15:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxMjIzNiM3NzgyNTc0IzIyMDUxNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-launches-change-seq-be-and-one-seq-be-to-strengthen-off-target-assessment-for-genome-editing-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MaxCyte launches CHANGE-seq-BE\u2122 and ONE-seq-BE\u2122 to strengthen off-target assessment for genome editing therapies"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/996619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=996619"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/996619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=996619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=996619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=996619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}